Previous 10 | Next 10 |
Compugen (NASDAQ: CGEN ) plans to initiate a Phase 1/2 clinical trial evaluating COM701, combined with Bristol-Myers Squibb's (NYSE: BMY ) Opdivo (nivolumab) and BMS-986207, in patients with solid tumors (including ovarian and endometrial cancers). The primary objective is to assess the sa...
Compugen ( CGEN ) Q4 results : Revenues: $0; R&D Expense: $4.3M (-42.7%); SG&A: $2.4M (+9.1%); Net loss: ($6.5M) (+30.9%); loss/share: ($0.10) (+37.5%); Quick Assets: $43.9M (-3.9%). More news on: Compugen Ltd., Healthcare stocks news, Earnings news and commentary, Stocks on the m...
Compugen (NASDAQ: CGEN ): Q4 GAAP EPS of -$0.10 beats by $0.01 . More news on: Compugen Ltd., Earnings news and commentary, Stocks on the move, Healthcare stocks news, Read more ...
HOLON, Israel , Feb. 20, 2020 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today reported financial results for the fourth quarter and full year ended December 31, 2019 . "2019 wa...
HOLON, Israel , Feb. 20, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced its plan to initiate a Phase 1/2 study evaluating a triple combination of Compugen's COM701, an ...
HOLON, Israel , Feb. 10, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company will release its fourth quarter and full year 2019 financial results on Thursday, ...
HOLON, Israel , Feb. 7, 2020 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced that its ongoing Phase 1 clinical trial evaluating COM701, a first-in-class therapeutic antibo...
HOLON, Israel , Feb. 4, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, announced today that the United States Patent and Trademark Office (USPTO) has granted the Company a new patent f...
Compugen Ltd.'s ( CGEN ) preliminary Phase 1 readout last November from its COM-701 (anti-PVRIG antibody) all-comers dose-escalation trial was very encouraging. Compugen is proving out the value and capability of its proprietary computational drug discovery platform with 3 of its drugs int...
HOLON, Israel , Jan. 29, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, announced today that The European Patent Office (EPO) has granted the Company a new patent for the use of any anti-PV...
News, Short Squeeze, Breakout and More Instantly...
Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors PR Newswire FDA clearance triggers a $30 million milestone payment from Gilead Company on track to initiate a Phase 1 trial for COM503, a differentiated antibody approach to harne...
Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024 PR Newswire HOLON, Israel , July 23, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target ...
Compugen to Present at Upcoming Antibody Industrial Symposium PR Newswire HOLON, Israel , June 17, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, t...